Exclusive: Column Group raises a new $400M+ fund and R&D hub for single-asset biologics companies
As the biotech industry grapples with how to fund drug development in a world of increasing research costs, rising drug prices and government-related risk, a legacy investor is taking a different approach for its 10th fund.
The Column Group told Endpoints News exclusively on Thursday that it has raised over $400 million for a new fund to back single-asset biologic companies derived from its extensive Rolodex of researchers and entrepreneurs. The fund will bring the group’s assets under management to around $4 billion.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.